Chronic HBV infection is common in remote Aboriginal and Torres Strait Islander communities, where resources are scarce and patients may have several concurrent illnesses.
The management of chronic HBV infection has changed over recent years, with greater application of serological and radiological investigations and new, more acceptable treatments for chronic liver disease, cirrhosis and hepatocellular carcinoma.
Optimal follow-up procedures for patients with chronic HBV infection are still being debated, but may not be applicable to Aboriginal and Torres Strait Islander communities where factors such as endemicity, remoteness, frequent comorbidities, shorter life expectancy and cultural differences in health priorities must be taken into consideration.
We have defined an algorithm to assist primary care providers caring for patients with chronic HBV infection in Aboriginal and Torres Strait Islander communities. Patients are divided into one of three categories for follow-up and referral based on clinical features, and results of liver enzyme and serological tests.
- 1. Condon JR, Warman G, Arnold L, editors. The health and welfare of Territorians. Darwin: Epidemiology Branch, Territory Health Services, 2001. Available at: http://www.nt.gov.au/health/health_gains/epidemiology/welfare_territorians.pdf (accessed Nov 2002).
- 2. Australian Bureau of Statistics and Australian Institute of Health and Welfare. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. Canberra: ABS, 2001. (Catalogue No. 4704.0.) Available at: http://www.abs.gov.au/Ausstats/abs@.nsf/Lookup/8D02FB93FD87ECDACA256D910000AD80 (link updated Nov 2005).
- 3. Cunningham J, Paradies Y. Mortality of Aboriginal and Torres Strait Islander Australians 1997. 3315.0. 17-4-2000. Canberra, Australian Bureau of Statistics. Occasional Paper. Available at: http://www.abs.gov.au/ausstats/abs%40.nsf/9cfdfe271b7930bbca2568b5007b8618/7dfa0774613c8e16ca2568ba001960ca!OpenDocument (accessed Nov 2002).
- 4. Gardner ID, Wan X, Simms PA, et al. Hepatitis B virus markers in children and staff in Northern Territory schools. Med J Aust 1992; 156: 638-641.
- 5. Burrell CJ, Cameron AS, Hart G, et al. Hepatitis B reservoirs and attack rates in an Australian community. A basis for vaccination and cross-infection policies. Med J Aust 1983; 2: 492-496.
- 6. Holman CDJ, Bucens MR, Quadros CF, Reid PM. Occurrence and distribution of hepatitis B infection in the Aboriginal population of Western Australia. Aust N Z J Med 1987; 17: 518-525.
- 7. Campbell DH, Sargent JW, Plant AJ. The prevalence of markers of infection with hepatitis B virus in a mixed race Australian community. Med J Aust 1989, 150: 489-492.
- 8. Dempsey KE, Condon JR. Mortality in the Northern Territory 1979-1997, Darwin: Territory Health Services, 1999. Available at: http://www.nt.gov.au/health/health_gains/epidemiology/mortality_NT_1979_1997.pdf (accessed Nov 2002).
- 9. Wan X, Mathews JD. Primary hepatocellular carcinoma in Aboriginal Australians. Aust J Public Health 1994; 18: 286-290.
- 10. Scrimgeour D. Screening Issues for Aboriginal people. CARPA Newsletter No. 24. Oct 1996, 4-10.
- 11. Farrell GC. Chronic viral hepatitis [Practice essentials – gastroenterology]. Med J Aust 1998; 168: 619-626.
- 12. Gastroenterological Society of Australia. Hepatitis B. New tests, new treatments, new recommendations. An information booklet for health care providers from the Digestive Health Foundation. 2nd edition. Sydney: Gastroenterological Society of Australia, 2000.
- 13. Asian Pacific Guidelines on the prevention and management of hepatitis B (core working party for Asia-Pacific Consensus on hepatitis B and C). Consensus statements on the prevention and management of hepatitis B and C in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15: 825-841.
- 14. Mahoney FJ. Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999: 12: 351-366.
- 15. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000; 76: 4-11.
- 16. Beasley PR, Hwang LY, Lin CC. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981; 2: 1129-1133.
- 17. Farrell GC. Towards the eradication of hepatitis B in Australia. Aust N Z J Med 1988; 18: 645.
- 18. De Jongh FE, Janssen HLA, de Man RA. Survival and prognostic indicators in hepatitis B surface antigen positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635.
- 19. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-194.
- 20. Strasser SI, McCaughan GW. Therapies for chronic hepatitis B: emerging roles for nucleoside analogues. Aust N Z J Med 2000; 30: 556-558.
- 21. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
- 22. Han DJ, Tae HK, Park SK, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71: 367-394.
- 23. Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 991-1008.
- 24. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaskan natives infected with chronic hepatitis B: a 16-year population based study. Hepatology 2000; 32: 842-846.
- 25. Lin D, Liaw Y. Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J Gastroenterol Hepatol 2001; 16: 553-559.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.